<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666926</url>
  </required_header>
  <id_info>
    <org_study_id>A8031001</org_study_id>
    <nct_id>NCT00666926</nct_id>
  </id_info>
  <brief_title>Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase
      (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography [PET]
      scans due to advanced non-hematologic malignancies, including pancreatic, head and neck, and
      prostatic neoplasms, and patients with other malignancies appropriate for serial biopsy.
      Screening consists of a Fluorodeoxyglucose Positron Emission Tomography [FDG-PET] and tumor
      imaging, medical history, physical examination, Eastern Cooperative Oncology Group [ECOG]
      performance status, blood draws, a pregnancy test for female patients of childbearing
      potential. Treatment consists of PF00562271 tablets continued until progression of disease,
      unacceptable toxicity, or patient request. Evaluations for bioactivity are measured by serial
      FDG-PET and blood tests for biomarkers related to FAK and PYK2 kinase activities.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline up to Cycle 1 Day 21 (C1.D21)</time_frame>
    <description>At least possibly attributable to study treatment (Tx): Grade (Gr) 4 neutropenia (absolute neutrophil count [ANC] &lt;500 cells/mm^3) for &gt;7 days or Gr 3 febrile neutropenia (ANC &lt;1000/mm^3, fever ≥38 degrees Celsius; Gr 4 thrombocytopenia (platelets &lt;25,000 cells/mm^3); Gr ≥3 non-hematologic toxicity despite adequate medical intervention; Gr ≥3 confirmed prolonged QTc interval (&gt;500 milliseconds [msec]); confirmed cardiac troponin I ≥99 percentile of reference range; Tx related toxicities with failure to receive ≥18 days Tx in 21-day cycle or inability to resume current dose level ≤14 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET)</measure>
    <time_frame>Baseline, C1.D14</time_frame>
    <description>Metabolic response demonstrated in any tumor reduction of ≥15% in tumor FDG standardized uptake value (SUV) in Cycle 1; based on the recommendations of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Participant must have had a baseline PET with at least 1 tumor lesion demonstrating an FDG SUV of ≥5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax): PF-00562271 C0.D1, C1.D1</measure>
    <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 morning (am) dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax): PF-00562271 C1.D14</measure>
    <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C0.D1, C1.D1</measure>
    <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C1.D14</measure>
    <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): PF-00562271 C0.D1, C1.D1</measure>
    <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
    <description>Area under the serum concentration time-curve from zero to the last measured concentration; nanograms multiplied by hours per milliliters (ng*hr/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): PF-00562271 C0.D1, C1.D1</measure>
    <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
    <description>AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Decay Half-life (t 1/2): PF-00562271 C0.D1, C1.D1</measure>
    <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
    <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F): PF-00562271 C0. D1, C1.D1</measure>
    <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Trough Concentration (Cmin): PF-00562271 C1.D14</measure>
    <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to the End of the Dosing Interval (AUCtau): PF-00562271 C1.D14</measure>
    <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio (Rac): PF-00562271 C1.D14</measure>
    <time_frame>Escalation (Esc) cohort: C0.D1: 0 hr, and 0.5, 1, 2, 4, 6, 7,12 hrs post dose; Expansion (Exp) cohort: C0:D1: 0 hr, and 1, 2, 4, 8 hrs post dose; Esc and Exp cohorts: C1.D14 0 hour, and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
    <description>Rac was the ratio of the Day 14 AUC0-tau (0 hour to last dose interval) and AUC during the corresponding time period after the lead-in dose (AUCtau C1.D14/AUCtau C0.D1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax): MDZ</measure>
    <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): MDZ</measure>
    <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
    <description>Area under the serum concentration time-curve from zero to the last measured concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): MDZ</measure>
    <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
    <description>AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax): MDZ</measure>
    <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Decay Half-life (t 1/2): MDZ</measure>
    <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
    <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F): MDZ</measure>
    <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Baseline up to 12 cycles (cycle=21days)</time_frame>
    <description>Best response recorded from start of treatment (Tx) until disease progression. Complete response: disappearance of all target lesions. Partial response: ≥30% decrease in sum of longest dimensions (LD) of target lesions referencing baseline sum LD. Progressive disease: ≥20% increase in sum LD of target lesions from smallest sum LD recorded since Tx start or appearance of ≥1 new lesions. Stable disease: neither sufficient shrinkage to=PR nor sufficient increase to=PD during first 6 weeks after Tx start referencing smallest sum LD since Tx start.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylated Focal Adhesion Kinase (pFAK)</measure>
    <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
    <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; FAK is overexpressed in a variety of human cancers. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylated Mitogen Activated Pathway Kinase (pMAPK)</measure>
    <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
    <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; MAPK regulates activities of several transcription factors. A defect in MAPK pathway leads to uncontrolled cell growth. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phospho-SRC (pSRC)</measure>
    <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
    <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; SRC proto-oncogenes are regulators of growth and differentiation of eukaryotic cells and are implicated in development of human tumors. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose; on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caspase-3</measure>
    <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
    <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Head and Neck Neoplasm</condition>
  <condition>Prostatic Neoplasm</condition>
  <condition>Pancreatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF00562271</intervention_name>
    <description>125 mg twice daily [BID] with food, tablet</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF00562271</intervention_name>
    <description>125 mg BID with food, tablet</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF00562271</intervention_name>
    <description>125 mg BID with food, tablet</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF00562271</intervention_name>
    <description>125 mg BID with food, tablet</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pancreatic, head and neck, and prostatic neoplasms, and patients with non-hematologic
             malignancies who have tumor appropriate for serial biopsy.

          -  Adequate organ function, including bilirubin less than 1.5 x ULN, and [Eastern
             Cooperative Oncology Group] ECOG performance status of 0-2.

        Exclusion Criteria:

          -  Clinically significant gastrointestinal abnormalities, requirement for systemic
             anticoagulants or potent CYP 3A4 inhibitors, and history of clinically significant
             cardiac or pulmonary disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8031001&amp;StudyName=%20Study%20Of%20PF-00562271%2C%20Including%20Patients%20With%20Pancreatic%2C%20Head%20And%20Neck%2C%20Prostatic%20Neoplasms</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <results_first_submitted>May 11, 2012</results_first_submitted>
  <results_first_submitted_qc>May 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2012</results_first_posted>
  <last_update_submitted>March 14, 2013</last_update_submitted>
  <last_update_submitted_qc>March 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Neoplasm</keyword>
  <keyword>Head and Neck neoplasm</keyword>
  <keyword>Prostatic neoplasms; Focal Adhesion Kinase</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>FDG-PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Expansion cohort (E1 or E2): participants were to be those enrolled at maximum tolerated dose level. E1: to have advanced disease likely to possess functional aberrations of pathways for tumorigenesis (represent focal adhesion kinase [FAK] expression). E2: to have disease characteristics associated with FAK expression and agree to repeat biopsies.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-00562271 5 mg BID</title>
          <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
        </group>
        <group group_id="P2">
          <title>PF-00562271 10 mg BID</title>
          <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P3">
          <title>PF-00562271 15 mg BID</title>
          <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P4">
          <title>PF-00562271 25 mg BID</title>
          <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P5">
          <title>PF-00562271 35 mg BID</title>
          <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P6">
          <title>PF-00562271 45 mg BID</title>
          <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P7">
          <title>PF-00562271 60 mg BID</title>
          <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P8">
          <title>PF-00562271 75 mg BID</title>
          <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (expansion cohort).
As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.</description>
        </group>
        <group group_id="P9">
          <title>PF-00562271 80 mg BID</title>
          <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P10">
          <title>PF-00562271 100 mg BID</title>
          <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort. Escalation and expansion cohorts were combined for reporting.</description>
        </group>
        <group group_id="P11">
          <title>PF-00562271 105 mg BID</title>
          <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="P12">
          <title>PF-00562271 125 mg BID</title>
          <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 (C1.D21) simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
Escalation and expansion cohorts were combined for reporting.</description>
        </group>
        <group group_id="P13">
          <title>PF-00562271 150 mg BID</title>
          <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
        </group>
        <group group_id="P14">
          <title>PF-00562271 125 mg QD</title>
          <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
        </group>
        <group group_id="P15">
          <title>PF-00562271 175 mg QD</title>
          <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
        </group>
        <group group_id="P16">
          <title>PF-00562271 225 mg QD</title>
          <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="33"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="33"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory abnormality</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="26"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="4"/>
                <participants group_id="P16" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>PF-00562271 dose escalation administered as 5 mg PO BID up to 150 mg PO BID or 125 mg PO QD up to 225 mg PO QD. Participants in the PF-00562271125 mg BID US E1 cohort administered MDZ 2 mg/mL as a single dose on C1.D1 and C1.D21 prior to PF-00562271 dosing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)</title>
        <description>At least possibly attributable to study treatment (Tx): Grade (Gr) 4 neutropenia (absolute neutrophil count [ANC] &lt;500 cells/mm^3) for &gt;7 days or Gr 3 febrile neutropenia (ANC &lt;1000/mm^3, fever ≥38 degrees Celsius; Gr 4 thrombocytopenia (platelets &lt;25,000 cells/mm^3); Gr ≥3 non-hematologic toxicity despite adequate medical intervention; Gr ≥3 confirmed prolonged QTc interval (&gt;500 milliseconds [msec]); confirmed cardiac troponin I ≥99 percentile of reference range; Tx related toxicities with failure to receive ≥18 days Tx in 21-day cycle or inability to resume current dose level ≤14 days.</description>
        <time_frame>Baseline up to Cycle 1 Day 21 (C1.D21)</time_frame>
        <population>Safety analysis set: All enrolled participants who started treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 75 mg BID</title>
            <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Cycle Dose Limiting Toxicities (DLTs)</title>
          <description>At least possibly attributable to study treatment (Tx): Grade (Gr) 4 neutropenia (absolute neutrophil count [ANC] &lt;500 cells/mm^3) for &gt;7 days or Gr 3 febrile neutropenia (ANC &lt;1000/mm^3, fever ≥38 degrees Celsius; Gr 4 thrombocytopenia (platelets &lt;25,000 cells/mm^3); Gr ≥3 non-hematologic toxicity despite adequate medical intervention; Gr ≥3 confirmed prolonged QTc interval (&gt;500 milliseconds [msec]); confirmed cardiac troponin I ≥99 percentile of reference range; Tx related toxicities with failure to receive ≥18 days Tx in 21-day cycle or inability to resume current dose level ≤14 days.</description>
          <population>Safety analysis set: All enrolled participants who started treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="33"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="4"/>
                <count group_id="O15" value="7"/>
                <count group_id="O16" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="2"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET)</title>
        <description>Metabolic response demonstrated in any tumor reduction of ≥15% in tumor FDG standardized uptake value (SUV) in Cycle 1; based on the recommendations of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Participant must have had a baseline PET with at least 1 tumor lesion demonstrating an FDG SUV of ≥5.</description>
        <time_frame>Baseline, C1.D14</time_frame>
        <population>Participants in the 125 mg BID expansion cohort with at least 1 dose of study treatment, at least 1 lesion with an SUV ≥5 at baseline, and an on-study PET assessment C1.D14 (Day 13 up to Day 17).</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tumor Metabolic Response (Reduction of ≥15%) in Positron Emission Tomography With F-18-fluorodeoxyglucose (FDG-PET)</title>
          <description>Metabolic response demonstrated in any tumor reduction of ≥15% in tumor FDG standardized uptake value (SUV) in Cycle 1; based on the recommendations of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Participant must have had a baseline PET with at least 1 tumor lesion demonstrating an FDG SUV of ≥5.</description>
          <population>Participants in the 125 mg BID expansion cohort with at least 1 dose of study treatment, at least 1 lesion with an SUV ≥5 at baseline, and an on-study PET assessment C1.D14 (Day 13 up to Day 17).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="26.4" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax): PF-00562271 C0.D1, C1.D1</title>
        <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 morning (am) dose</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis set: all participants with at least 1 dose of study treatment and at least 1 of the PK parameters of interest estimated in at least 1 treatment period. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 75 mg BID (Expansion Cohort)</title>
            <description>PF-00562271 administered as 75 mg PO BID with food w/food. As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.</description>
          </group>
          <group group_id="O17">
            <title>PF-00562271 100 mg BID (Expansion Cohort)</title>
            <description>PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O18">
            <title>PF-00562271 125 mg BID (Expansion Cohort)</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax): PF-00562271 C0.D1, C1.D1</title>
          <population>Pharmacokinetic (PK) parameter analysis set: all participants with at least 1 dose of study treatment and at least 1 of the PK parameters of interest estimated in at least 1 treatment period. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="8"/>
                <count group_id="O16" value="1"/>
                <count group_id="O17" value="4"/>
                <count group_id="O18" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.63" spread="4"/>
                    <measurement group_id="O2" value="71.13" spread="24"/>
                    <measurement group_id="O3" value="138.8" spread="73"/>
                    <measurement group_id="O4" value="130.1" spread="176"/>
                    <measurement group_id="O5" value="306.1" spread="28"/>
                    <measurement group_id="O6" value="312.9" spread="108"/>
                    <measurement group_id="O7" value="363.2" spread="37"/>
                    <measurement group_id="O8" value="597.6" spread="2"/>
                    <measurement group_id="O9" value="397.3" spread="91"/>
                    <measurement group_id="O10" value="1018" spread="48"/>
                    <measurement group_id="O11" value="1236" spread="49"/>
                    <measurement group_id="O12" value="647.2" spread="52"/>
                    <measurement group_id="O13" value="1110" spread="35"/>
                    <measurement group_id="O14" value="1528" spread="57"/>
                    <measurement group_id="O15" value="2605" spread="35"/>
                    <measurement group_id="O16" value="421.0" spread="0"/>
                    <measurement group_id="O17" value="474.6" spread="44"/>
                    <measurement group_id="O18" value="747.9" spread="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax): PF-00562271 C1.D14</title>
        <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
        <population>PK parameter analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax): PF-00562271 C1.D14</title>
          <population>PK parameter analysis set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="2"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.65" spread="80"/>
                    <measurement group_id="O2" value="134.7" spread="55"/>
                    <measurement group_id="O3" value="309.6" spread="58"/>
                    <measurement group_id="O4" value="307.7" spread="145"/>
                    <measurement group_id="O5" value="655.4" spread="72"/>
                    <measurement group_id="O6" value="1105" spread="46"/>
                    <measurement group_id="O7" value="1083" spread="84"/>
                    <measurement group_id="O8" value="1767" spread="61"/>
                    <measurement group_id="O9" value="2295" spread="74"/>
                    <measurement group_id="O10" value="2580" spread="62"/>
                    <measurement group_id="O11" value="2947" spread="62"/>
                    <measurement group_id="O12" value="3445" spread="65"/>
                    <measurement group_id="O13" value="2021" spread="17"/>
                    <measurement group_id="O14" value="3136" spread="43"/>
                    <measurement group_id="O15" value="4438" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C0.D1, C1.D1</title>
        <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
        <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 75 mg BID (Expansion Cohort)</title>
            <description>PF-00562271 administered as 75 mg PO BID with food w/food. As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.</description>
          </group>
          <group group_id="O17">
            <title>PF-00562271 100 mg BID (Expansion Cohort)</title>
            <description>PF-00562271 administered as 100 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O18">
            <title>PF-00562271 125 mg BID (Expansion Cohort)</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food. As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C0.D1, C1.D1</title>
          <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="8"/>
                <count group_id="O16" value="1"/>
                <count group_id="O17" value="4"/>
                <count group_id="O18" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.500" lower_limit="0.500" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O8" value="2.00" lower_limit="0.500" upper_limit="8.00"/>
                    <measurement group_id="O9" value="4.00" lower_limit="4.00" upper_limit="4.00"/>
                    <measurement group_id="O10" value="2.00" lower_limit="0.500" upper_limit="6.00"/>
                    <measurement group_id="O11" value="4.00" lower_limit="0.500" upper_limit="8.00"/>
                    <measurement group_id="O12" value="4.00" lower_limit="0.500" upper_limit="8.00"/>
                    <measurement group_id="O13" value="5.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O14" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O15" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O16" value="4.00" lower_limit="4.00" upper_limit="4.00"/>
                    <measurement group_id="O17" value="6.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O18" value="4.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C1.D14</title>
        <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
        <population>PK parameter analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax): PF-00562271 C1.D14</title>
          <population>PK parameter analysis set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="2"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.500" upper_limit="0.500"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.500" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="2.00" upper_limit="12.0"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O7" value="1.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O9" value="2.25" lower_limit="0.000" upper_limit="12.0"/>
                    <measurement group_id="O10" value="3.00" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O11" value="4.00" lower_limit="0.000" upper_limit="12.0"/>
                    <measurement group_id="O12" value="7.00" lower_limit="6.00" upper_limit="8.00"/>
                    <measurement group_id="O13" value="5.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O14" value="2.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O15" value="2.50" lower_limit="0.500" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): PF-00562271 C0.D1, C1.D1</title>
        <description>Area under the serum concentration time-curve from zero to the last measured concentration; nanograms multiplied by hours per milliliters (ng*hr/mL).</description>
        <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
        <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): PF-00562271 C0.D1, C1.D1</title>
          <description>Area under the serum concentration time-curve from zero to the last measured concentration; nanograms multiplied by hours per milliliters (ng*hr/mL).</description>
          <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.13" spread="47"/>
                    <measurement group_id="O2" value="233.8" spread="14"/>
                    <measurement group_id="O3" value="348.1" spread="67"/>
                    <measurement group_id="O4" value="295.6" spread="213"/>
                    <measurement group_id="O5" value="1205" spread="6"/>
                    <measurement group_id="O6" value="2364" spread="118"/>
                    <measurement group_id="O7" value="1735" spread="67"/>
                    <measurement group_id="O8" value="4407" spread="42"/>
                    <measurement group_id="O9" value="3501" spread="171"/>
                    <measurement group_id="O10" value="10600" spread="61"/>
                    <measurement group_id="O11" value="11900" spread="163"/>
                    <measurement group_id="O12" value="6083" spread="134"/>
                    <measurement group_id="O13" value="16330" spread="12"/>
                    <measurement group_id="O14" value="20830" spread="66"/>
                    <measurement group_id="O15" value="38600" spread="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): PF-00562271 C0.D1, C1.D1</title>
        <description>AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
        <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): PF-00562271 C0.D1, C1.D1</title>
          <description>AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
          <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.24" spread="48"/>
                    <measurement group_id="O2" value="239.6" spread="14"/>
                    <measurement group_id="O3" value="354.1" spread="68"/>
                    <measurement group_id="O4" value="574.1" spread="18"/>
                    <measurement group_id="O5" value="1222" spread="6"/>
                    <measurement group_id="O6" value="2399" spread="118"/>
                    <measurement group_id="O7" value="1759" spread="66"/>
                    <measurement group_id="O8" value="4507" spread="44"/>
                    <measurement group_id="O9" value="6588" spread="65"/>
                    <measurement group_id="O10" value="10880" spread="71"/>
                    <measurement group_id="O11" value="5534" spread="271"/>
                    <measurement group_id="O12" value="6101" spread="135"/>
                    <measurement group_id="O13" value="16770" spread="13"/>
                    <measurement group_id="O14" value="21190" spread="65"/>
                    <measurement group_id="O15" value="37560" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Decay Half-life (t 1/2): PF-00562271 C0.D1, C1.D1</title>
        <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half.</description>
        <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
        <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Decay Half-life (t 1/2): PF-00562271 C0.D1, C1.D1</title>
          <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half.</description>
          <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.990" spread="0.60811"/>
                    <measurement group_id="O2" value="2.078" spread="0.40901"/>
                    <measurement group_id="O3" value="2.173" spread="0.38799"/>
                    <measurement group_id="O4" value="2.837" spread="1.2176"/>
                    <measurement group_id="O5" value="2.897" spread="0.53304"/>
                    <measurement group_id="O6" value="5.270" spread="1.8993"/>
                    <measurement group_id="O7" value="3.365" spread="0.88410"/>
                    <measurement group_id="O8" value="4.770" spread="0.51069"/>
                    <measurement group_id="O9" value="5.025" spread="0.62933"/>
                    <measurement group_id="O10" value="6.180" spread="2.9592"/>
                    <measurement group_id="O11" value="3.853" spread="1.4332"/>
                    <measurement group_id="O12" value="4.407" spread="1.9318"/>
                    <measurement group_id="O13" value="8.388" spread="1.9370"/>
                    <measurement group_id="O14" value="5.937" spread="1.1016"/>
                    <measurement group_id="O15" value="7.948" spread="2.7254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F): PF-00562271 C0. D1, C1.D1</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
        <time_frame>Escalation cohorts: C0.D1 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hrs post dose; Expansion E1 US cohort: C1.D1 0 hr (prior to MDZ dose); E1 non-US and E2 cohort: C1.D1 0 hr and 0.5, 1, 2, 4 hrs post C1.D1 am dose</time_frame>
        <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F): PF-00562271 C0. D1, C1.D1</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
          <population>PK parameter analysis set. Escalation cohorts: Cycle 0 48 hours post dose timepoint = C1.D1.</population>
          <units>milliliters per minute (mL/min)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="3"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="964.2" spread="48"/>
                    <measurement group_id="O2" value="702.1" spread="17"/>
                    <measurement group_id="O3" value="707.2" spread="68"/>
                    <measurement group_id="O4" value="726.0" spread="18"/>
                    <measurement group_id="O5" value="478.0" spread="6"/>
                    <measurement group_id="O6" value="312.3" spread="118"/>
                    <measurement group_id="O7" value="568.3" spread="66"/>
                    <measurement group_id="O8" value="295.5" spread="44"/>
                    <measurement group_id="O9" value="253.2" spread="64"/>
                    <measurement group_id="O10" value="160.9" spread="71"/>
                    <measurement group_id="O11" value="475.5" spread="553"/>
                    <measurement group_id="O12" value="516.9" spread="120"/>
                    <measurement group_id="O13" value="124.0" spread="13"/>
                    <measurement group_id="O14" value="137.7" spread="65"/>
                    <measurement group_id="O15" value="99.85" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Serum Trough Concentration (Cmin): PF-00562271 C1.D14</title>
        <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
        <population>PK parameter analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Serum Trough Concentration (Cmin): PF-00562271 C1.D14</title>
          <population>PK parameter analysis set</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="2"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01349">Geometric CV % was not calculated for treatment groups with N &lt;3.</measurement>
                    <measurement group_id="O2" value="0.8059" spread="12668339981"/>
                    <measurement group_id="O3" value="48.96" spread="89"/>
                    <measurement group_id="O4" value="33.11" spread="1046"/>
                    <measurement group_id="O5" value="145.8" spread="131"/>
                    <measurement group_id="O6" value="315.3" spread="112"/>
                    <measurement group_id="O7" value="359.8" spread="80"/>
                    <measurement group_id="O8" value="594.5" spread="134"/>
                    <measurement group_id="O9" value="1005" spread="117"/>
                    <measurement group_id="O10" value="1131" spread="67"/>
                    <measurement group_id="O11" value="1253" spread="86"/>
                    <measurement group_id="O12" value="0.4111">Geometric CV % was not calculated for treatment groups with N &lt;3.</measurement>
                    <measurement group_id="O13" value="439.6" spread="48"/>
                    <measurement group_id="O14" value="634.7" spread="92"/>
                    <measurement group_id="O15" value="1129" spread="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to the End of the Dosing Interval (AUCtau): PF-00562271 C1.D14</title>
        <time_frame>Escalation and Expansion E1 and E2 cohorts: C1.D14 0 hour (0 hr=pre-dose PF-00562271), and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
        <population>PK parameter analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to the End of the Dosing Interval (AUCtau): PF-00562271 C1.D14</title>
          <population>PK parameter analysis set</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="2"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.3" spread="53"/>
                    <measurement group_id="O2" value="447.2" spread="122"/>
                    <measurement group_id="O3" value="1573" spread="80"/>
                    <measurement group_id="O4" value="1476" spread="238"/>
                    <measurement group_id="O5" value="4519" spread="84"/>
                    <measurement group_id="O6" value="8357" spread="61"/>
                    <measurement group_id="O7" value="8173" spread="74"/>
                    <measurement group_id="O8" value="12920" spread="86"/>
                    <measurement group_id="O9" value="20010" spread="76"/>
                    <measurement group_id="O10" value="21120" spread="62"/>
                    <measurement group_id="O11" value="24340" spread="77"/>
                    <measurement group_id="O12" value="26200" spread="22"/>
                    <measurement group_id="O13" value="24470" spread="30"/>
                    <measurement group_id="O14" value="43140" spread="50"/>
                    <measurement group_id="O15" value="68780" spread="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Accumulation Ratio (Rac): PF-00562271 C1.D14</title>
        <description>Rac was the ratio of the Day 14 AUC0-tau (0 hour to last dose interval) and AUC during the corresponding time period after the lead-in dose (AUCtau C1.D14/AUCtau C0.D1).</description>
        <time_frame>Escalation (Esc) cohort: C0.D1: 0 hr, and 0.5, 1, 2, 4, 6, 7,12 hrs post dose; Expansion (Exp) cohort: C0:D1: 0 hr, and 1, 2, 4, 8 hrs post dose; Esc and Exp cohorts: C1.D14 0 hour, and 0.5, 1, 2, 4, 6, 8, 12 (if BID) or 24 (if QD) hrs post am dose</time_frame>
        <population>PK parameter analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Accumulation Ratio (Rac): PF-00562271 C1.D14</title>
          <description>Rac was the ratio of the Day 14 AUC0-tau (0 hour to last dose interval) and AUC during the corresponding time period after the lead-in dose (AUCtau C1.D14/AUCtau C0.D1).</description>
          <population>PK parameter analysis set</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.864" spread="4"/>
                    <measurement group_id="O2" value="2.997" spread="26"/>
                    <measurement group_id="O3" value="4.522" spread="50"/>
                    <measurement group_id="O4" value="5.061" spread="66"/>
                    <measurement group_id="O5" value="3.899" spread="80"/>
                    <measurement group_id="O6" value="5.038" spread="125"/>
                    <measurement group_id="O7" value="5.060" spread="99"/>
                    <measurement group_id="O8" value="3.638" spread="45"/>
                    <measurement group_id="O9" value="5.581" spread="57"/>
                    <measurement group_id="O10" value="2.967" spread="18"/>
                    <measurement group_id="O11" value="3.608" spread="49"/>
                    <measurement group_id="O12" value="1.961" spread="20"/>
                    <measurement group_id="O13" value="2.293" spread="52"/>
                    <measurement group_id="O14" value="1.118" spread="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration (Cmax): MDZ</title>
        <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
        <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax): MDZ</title>
          <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0.D1 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.14" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1.D21 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.40" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Participants in the PF-00562271 125 mg BID cohort who received MDZ (test) administered prior to PF-00562271 (reference) dosing.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (percent) test / reference</param_type>
            <param_value>155.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>109.66</ci_lower_limit>
            <ci_upper_limit>220.95</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means Day 21 versus Day 1. Values have been transformed from the log scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): MDZ</title>
        <description>Area under the serum concentration time-curve from zero to the last measured concentration.</description>
        <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
        <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): MDZ</title>
          <description>Area under the serum concentration time-curve from zero to the last measured concentration.</description>
          <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0.D1 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.44" spread="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1.D21 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.0" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Participants in the PF-00562271 125 mg BID cohort who received MDZ (test) administered prior to PF-00562271 (reference) dosing.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (percent) test / reference</param_type>
            <param_value>315.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>227.60</ci_lower_limit>
            <ci_upper_limit>437.97</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means Day 21 versus Day 1. Values have been transformed from the log scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): MDZ</title>
        <description>AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
        <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
        <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf): MDZ</title>
          <description>AUCinf = area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).</description>
          <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0.D1 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.79" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1.D21 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.3" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Participants in the PF-00562271 125 mg BID cohort who received MDZ (test) administered prior to PF-00562271 (reference) dosing.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (percent) test / reference</param_type>
            <param_value>496.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>206.24</ci_lower_limit>
            <ci_upper_limit>1195.92</ci_upper_limit>
            <estimate_desc>Ratio of adjusted geometric means Day 21 versus Day 1. Values have been transformed from the log scale.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Serum Concentration (Tmax): MDZ</title>
        <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
        <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Serum Concentration (Tmax): MDZ</title>
          <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0.D1 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.500" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1.D21 (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.500" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Decay Half-life (t 1/2): MDZ</title>
        <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half.</description>
        <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
        <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Decay Half-life (t 1/2): MDZ</title>
          <description>Serum decay half-life is the time measured for the serum concentration to decrease by one half.</description>
          <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0.D1 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.045" spread="1.7221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1.D21 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.764" spread="0.68475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Oral Clearance (CL/F): MDZ</title>
        <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
        <time_frame>C0.D1, C1.D21 Expansion cohort E1 US sites only: 0 hr (prior to MDZ dosing) and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hrs post MDZ dose</time_frame>
        <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F): MDZ</title>
          <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.</description>
          <population>N=participants in the PK parameter analysis set who received MDZ dosing prior to PF-00562271 in the 125 mg BID cohort; (n)=number of participants with analyzable data at observation.</population>
          <units>mL/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C0.D1 (n=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20090" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C1.D21 (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4709" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>Best response recorded from start of treatment (Tx) until disease progression. Complete response: disappearance of all target lesions. Partial response: ≥30% decrease in sum of longest dimensions (LD) of target lesions referencing baseline sum LD. Progressive disease: ≥20% increase in sum LD of target lesions from smallest sum LD recorded since Tx start or appearance of ≥1 new lesions. Stable disease: neither sufficient shrinkage to=PR nor sufficient increase to=PD during first 6 weeks after Tx start referencing smallest sum LD since Tx start.</description>
        <time_frame>Baseline up to 12 cycles (cycle=21days)</time_frame>
        <population>RECIST response analysis set: all enrolled participants who had an adequate baseline tumor assessment, measureable disease and who started treatment. N=number of participants with evaluable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 75 mg BID</title>
            <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Overall Response as Measured Using the Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>Best response recorded from start of treatment (Tx) until disease progression. Complete response: disappearance of all target lesions. Partial response: ≥30% decrease in sum of longest dimensions (LD) of target lesions referencing baseline sum LD. Progressive disease: ≥20% increase in sum LD of target lesions from smallest sum LD recorded since Tx start or appearance of ≥1 new lesions. Stable disease: neither sufficient shrinkage to=PR nor sufficient increase to=PD during first 6 weeks after Tx start referencing smallest sum LD since Tx start.</description>
          <population>RECIST response analysis set: all enrolled participants who had an adequate baseline tumor assessment, measureable disease and who started treatment. N=number of participants with evaluable data at observation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="31"/>
                <count group_id="O13" value="3"/>
                <count group_id="O14" value="3"/>
                <count group_id="O15" value="6"/>
                <count group_id="O16" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="11"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="3"/>
                    <measurement group_id="O16" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="15"/>
                    <measurement group_id="O13" value="3"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indeterminate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="1"/>
                    <measurement group_id="O16" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phosphorylated Focal Adhesion Kinase (pFAK)</title>
        <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; FAK is overexpressed in a variety of human cancers. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
        <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
        <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 75 mg BID</title>
            <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphorylated Focal Adhesion Kinase (pFAK)</title>
          <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; FAK is overexpressed in a variety of human cancers. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
          <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phosphorylated Mitogen Activated Pathway Kinase (pMAPK)</title>
        <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; MAPK regulates activities of several transcription factors. A defect in MAPK pathway leads to uncontrolled cell growth. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
        <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
        <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 75 mg BID</title>
            <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphorylated Mitogen Activated Pathway Kinase (pMAPK)</title>
          <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; MAPK regulates activities of several transcription factors. A defect in MAPK pathway leads to uncontrolled cell growth. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
          <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phospho-SRC (pSRC)</title>
        <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; SRC proto-oncogenes are regulators of growth and differentiation of eukaryotic cells and are implicated in development of human tumors. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose; on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
        <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
        <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 75 mg BID</title>
            <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Phospho-SRC (pSRC)</title>
          <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; SRC proto-oncogenes are regulators of growth and differentiation of eukaryotic cells and are implicated in development of human tumors. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose; on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
          <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caspase-3</title>
        <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
        <time_frame>Baseline (up to 28 days prior to first dose) up to 12 cycles (cycle=21days)</time_frame>
        <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00562271 5 mg BID</title>
            <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
          </group>
          <group group_id="O2">
            <title>PF-00562271 10 mg BID</title>
            <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O3">
            <title>PF-00562271 15 mg BID</title>
            <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O4">
            <title>PF-00562271 25 mg BID</title>
            <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O5">
            <title>PF-00562271 35 mg BID</title>
            <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O6">
            <title>PF-00562271 45 mg BID</title>
            <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O7">
            <title>PF-00562271 60 mg BID</title>
            <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O8">
            <title>PF-00562271 75 mg BID</title>
            <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (escalation cohort).
As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID cohort.</description>
          </group>
          <group group_id="O9">
            <title>PF-00562271 80 mg BID</title>
            <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O10">
            <title>PF-00562271 100 mg BID</title>
            <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort.</description>
          </group>
          <group group_id="O11">
            <title>PF-00562271 105 mg BID</title>
            <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
          </group>
          <group group_id="O12">
            <title>PF-00562271 125 mg BID</title>
            <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.</description>
          </group>
          <group group_id="O13">
            <title>PF-00562271 150 mg BID</title>
            <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
          </group>
          <group group_id="O14">
            <title>PF-00562271 125 mg QD</title>
            <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
          </group>
          <group group_id="O15">
            <title>PF-00562271 175 mg QD</title>
            <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
          </group>
          <group group_id="O16">
            <title>PF-00562271 225 mg QD</title>
            <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
          </group>
        </group_list>
        <measure>
          <title>Caspase-3</title>
          <description>Analysis of tumor specimens to assess FAK-related biomarkers for potential predictors of response markers to PF-00562271; sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. For dose escalation cohorts and expansion cohort E1, pre-treatment tumor biopsy collected between Day -28 and first PF-00562271 dose and on-treatment tumor biopsy collected 2 to 8 hours after PF-00562271 dose during Cycle 1 between day 12 and 16. In addition, up to 10 participants in cohort E2 were to be enrolled for serial biopsies.</description>
          <population>Data was not summarized as samples were processed and analyzed later than 3 days after collection and thus the data were considered unusable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are recorded from the time of first dose of study treatment up to 28 days after last dose of study treatment or until start of new anti-cancer treatment, whichever occurs first.</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>PF-00562271 5 mg BID</title>
          <description>PF-00562271 administered as 5 milligrams (mg) orally (PO) twice a day (BID) without food (w/o food: no food within 2 hours prior to dosing) (escalation cohort).</description>
        </group>
        <group group_id="E2">
          <title>PF-00562271 10 mg BID</title>
          <description>PF-00562271 administered as 10 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E3">
          <title>PF-00562271 15 mg BID</title>
          <description>PF-00562271 administered as 15 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E4">
          <title>PF-00562271 25 mg BID</title>
          <description>PF-00562271 administered as 25 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E5">
          <title>PF-00562271 35 mg BID</title>
          <description>PF-00562271 administered as 35 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E6">
          <title>PF-00562271 45 mg BID</title>
          <description>PF-00562271 administered as 45 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E7">
          <title>PF-00562271 60 mg BID</title>
          <description>PF-00562271 administered as 60 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E8">
          <title>PF-00562271 75 mg BID</title>
          <description>PF-00562271 administered as 75 mg PO BID with food (w/food: regular meal 200 to 800 calories) (expansion cohort).
As of July 2008, participants newly enrolled to the expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participant who was not able to titrate higher than 75 mg BID was reported in the 75 mg BID expansion cohort.</description>
        </group>
        <group group_id="E9">
          <title>PF-00562271 80 mg BID</title>
          <description>PF-00562271 administered as 80 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E10">
          <title>PF-00562271 100 mg BID</title>
          <description>PF-00562271 administered as 100 mg BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3. Participants who were not able to titrate higher than 100 mg BID were reported in the 100 mg BID cohort. Escalation and expansion cohorts were combined for reporting.</description>
        </group>
        <group group_id="E11">
          <title>PF-00562271 105 mg BID</title>
          <description>PF-00562271 administered as 105 mg PO BID w/o food (escalation cohort).</description>
        </group>
        <group group_id="E12">
          <title>PF-00562271 125 mg BID</title>
          <description>PF-00562271 administered as 125 mg PO BID w/food (escalation cohort). As of July 2008, participants newly enrolled to expansion cohort or who restarted treatment after dose delay associated with adverse event(s) were dosed according to intra-participant escalation (up-titration w/food): 75 mg BID week 1; 100 mg BID week 2; 125 mg BID week 3.
Additional participants were to be enrolled to the expansion cohort at the maximum tolerated dose (MTD) 125 mg BID (expansion cohort [E1 or E2]); E1 cohort United States (US) participants received Midazolam (MDZ) syrup 2 mg per milliliter (mg/mL) as a single PO dose 24 hours prior to first PF-00562271 dose (w/o food 2 hours prior to and after MDZ dosing) and on Cycle 1, Day 21 simultaneously with PF-00562271 dosing (w/food). E1 participants outside the US and E2 participants were not dosed with MDZ.
Escalation and expansion cohorts were combined for reporting.</description>
        </group>
        <group group_id="E13">
          <title>PF-00562271 150 mg BID</title>
          <description>PF-00562271 administered as 150 mg PO BID w/food (escalation cohort).</description>
        </group>
        <group group_id="E14">
          <title>PF-00562271 125 mg QD</title>
          <description>PF-00562271 administered as 125 mg PO once a day (QD) w/o food (escalation cohort).</description>
        </group>
        <group group_id="E15">
          <title>PF-00562271 175 mg QD</title>
          <description>PF-00562271 administered as 175 mg PO QD w/o food (escalation cohort).</description>
        </group>
        <group group_id="E16">
          <title>PF-00562271 225 mg QD</title>
          <description>PF-00562271 administered as 225 mg PO QD w/o food (escalation cohort).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ureteral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dysacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="22" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Red man syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Corrective lens user</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>PET and RECIST Response Analysis Sets as defined in Protocol Amendment 3 dated 20Mar2007 are reported in Basic Results per the revised definitions in Statistical Analysis Plan version 2 dated 11Apr2008.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mitchell Keegan</name_or_title>
      <organization>Verastem, Inc.</organization>
      <phone>617-252-9300</phone>
      <email>mkeegan@verastem.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

